Abrilada (Adalimumab)

Description

Abrilada (adalimumab-afzb) is a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-a), a pro-inflammatory cytokine implicated in several chronic inflammatory and autoimmune diseases. By blocking TNF-a interaction with its cell surface receptors, Abrilada modulates the inflammatory response and helps control disease activity. It is approved for the treatment of multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa.

Directions

Abrilada is administered by subcutaneous injection, and dosing varies by indication and patient profile. Examples include:

• Rheumatoid arthritis (adults): 40 mg every other week

• Crohn’s disease (adults): 160 mg initially, followed by 80 mg at week 2, then 40 mg every other week

• Plaque psoriasis: 80 mg initial dose, then 40 mg every other week starting one week later

Abrilada is available as a prefilled syringe or autoinjector. It should be stored refrigerated and brought to room temperature before injection. Injections should be given in the thigh or abdomen and rotated to reduce the risk of site reactions.

Ingredients

Each 0.8 mL of Abrilada contains:

• Adalimumab-afzb 40 mg

• Histidine

• Histidine hydrochloride monohydrate

• Sucrose

• Polysorbate 80

• Water for injection

Abrilada is citrate-free, latex-free, and preservative-free, designed to minimize injection site discomfort.

Contraindications

Abrilada is contraindicated in patients with:

• Hypersensitivity to adalimumab or any excipients

• Active tuberculosis or other severe infections

• Moderate to severe heart failure in certain indications

Cautions

Before initiating Abrilada, screen for latent or active tuberculosis, and consider hepatitis B screening. Patients should be monitored for infections, malignancies, demyelinating diseases, cytopenias, and liver function abnormalities during therapy. Concurrent use with other biologic immunosuppressants is not recommended. Live vaccines should be avoided during treatment. Caution is also warranted in patients with a history of chronic or recurrent infections or underlying conditions predisposing them to infection.

Side Effects

Common side effects of Abrilada include:

• Injection site reactions (redness, itching, pain)

• Upper respiratory tract infections

• Headache

• Nausea

• Rash

• Sinusitis

Serious adverse effects may include:

• Serious infections (e.g., TB, invasive fungal, opportunistic infections)

• Malignancies (e.g., lymphoma, skin cancer)

• Hepatitis B reactivation

• Demyelinating disorders

• Congestive heart failure exacerbation

• Lupus-like syndrome

• Severe hypersensitivity reactions

Product Code : 14372